Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma.

Royal, R E; Steinberg, S M; Krouse, R S; Heywood, G; White, D E; Hwu, P; Marincola, F M; Parkinson, D R; Schwartzentruber, D J; Topalian, S L; Yang, J C; Rosenberg, S A

Royal, R E; Steinberg, S M; Krouse, R S; Heywood, G; White, D E; Hwu, P; Marincola, F M; Parkinson, D R; Schwartzentruber, D J; Topalian, S L; Yang, J C; Rosenberg, S A.

Affiliation

Royal RE; Surgery Branch and Biostatistics and Data Management Section, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1502, USA.

Cancer J Sci Am ; 2(2): 91-8, 1996.

Article in En | MEDLINE | ID: mdl-9166506

Subject(s)

Immunotherapy; Interleukin-2/therapeutic use; Kidney Neoplasms/drug therapy; Melanoma/drug therapy; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Kidney Neoplasms/pathology; Lymphocytosis/chemically induced; Male; Melanoma/pathology; Middle Aged; Neoplasm Metastasis/drug therapy; Prognosis; Recombinant Proteins/therapeutic use; Thrombocytopenia/chemically induced; Treatment Outcome

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Interleukin-2 / Immunotherapy / Kidney Neoplasms / Melanoma Type of study: Prognostic_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Cancer J Sci Am Journal subject: NEOPLASIAS Year: 1996 Document type: Article Affiliation country: United States Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links